Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Xalkori in advanced NSCLC with ALK or ROS1 rearrangements
CTR20190184Phase 4Terminated
- Sponsor
- Pfizer
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started May 2019; status: terminated.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190184.